公司概述
Cuprina Holdings (Cayman) Limited operates as a biomedical and biotechnology enterprise dedicated to the development and commercialization of solutions for the management of chronic wounds. The company specifically manufactures and distributes a line of medical-grade sterile blowfly larvae bio-dressing products, which function as biological treatments for wound care. This operational focus places the firm within the Healthcare sector, specifically under the Medical Instruments & Supplies industry, where it aims to provide specialized biologics for clinical applications. The company currently maintains a market capitalization of $7.58 million and employs 14 individuals, while reporting trailing twelve-month revenues of $30,331. These valuation and revenue figures indicate a very small-scale operation with minimal market penetration, suggesting that the firm is in an early-stage development or niche distribution phase rather than a mature commercial entity.
财务健康
The company reported trailing twelve-month revenues of $30,331 against a net income of -$2,831,603 and an EBITDA of -$2,810,243. The substantial disparity between the nominal revenue and the massive negative net income reveals a cost structure where operating expenses and research costs vastly exceed sales proceeds, leading to a significant operating loss. Free cash flow stands at -$7,248,589, which indicates that the company is currently burning through its cash reserves to fund operations and development efforts without generating positive cash flow. The gross margin is reported at -69.2%, while the operating margin is -8643.0% and the profit margin is 0.0%, all of which reflect severe inefficiencies or accounting adjustments that result in negative profitability across all major margin lines. On the balance sheet, the company holds $4.17 million in cash against $3.14 million in debt, resulting in a debt-to-equity ratio of 40.86, which suggests a leveraged position where equity is relatively low compared to debt obligations. Despite the negative earnings, the current ratio of 3.58 indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a degree of short-term liquidity buffer. Return on Equity is -139.1% and Return on Assets is -28.4%, metrics that reveal management has not yet been effective in generating positive returns on the capital invested or assets held, highlighting the ongoing challenges in achieving financial sustainability.
估值评估
The trailing P/E ratio is N/A and the forward P/E is also N/A, implying that traditional earnings-based valuation models cannot be applied due to the company's lack of positive earnings and the absence of projected earnings growth. The price-to-book ratio is 1.27, which indicates that the market is valuing the company at a slight premium of 27% over its book value, despite the company's negative earnings and cash burn. The price-to-sales ratio is exceptionally high at 249.85, and the EV/EBITDA stands at -2.33, suggesting that investors are pricing the stock based on speculative potential or asset backing rather than current profitability or sales efficiency. The 52-week high is $9.50 and the 52-week low is $0.28, meaning the current trading price sits significantly below the annual peak but far above the recent lows, reflecting high volatility and wide trading ranges typical of micro-cap biotechnology stocks. The beta is N/A, which means there is insufficient historical data or market correlation available to quantify the stock's price volatility relative to the broader market movements.
Growth & Income
Revenue growth year-over-year is -43.9%, while earnings growth year-over-year is N/A, indicating that the company is contracting in terms of sales and has not yet established a positive earnings trajectory to measure growth against. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests its limited resources into research and development rather than distributing income to shareholders. The absence of a dividend policy is consistent with the company's stage of development, where capital preservation for product commercialization takes precedence over shareholder income distributions. Overall, the growth and income profile is characterized by negative revenue momentum and a complete lack of income generation, positioning Cuprina Holdings as a high-risk, non-income-generating investment reliant on future product successes.